Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients.

[1]  H. Malluche,et al.  Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  C. Coureau,et al.  Parathyroid hormone (PTH)/PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency. , 1995, Endocrinology.

[3]  S. Massry,et al.  Down-regulation of PTH-PTHrP receptor of heart in CRF: role of [Ca2+]i. , 1995, Kidney international.

[4]  R. Vanholder,et al.  The biological action of calcitriol in renal failure. , 1994, Kidney international.

[5]  H. Malluche,et al.  Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. , 1994, Kidney international.

[6]  M. Monier‐Faugere,et al.  The role of bone biopsy in the management of patients with renal osteodystrophy. , 1994, Journal of the American Society of Nephrology : JASN.

[7]  L. Kedes,et al.  PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. , 1994, American journal of nephrology.

[8]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[9]  B. Descamps-Latscha,et al.  Long-term dialysis and cellular immunity: a critical survey. , 1993, Kidney international. Supplement.

[10]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[11]  E. Ogata,et al.  Regulation of parathyroid hormone synthesis in chronic renal failure in rats. , 1991, Kidney international.

[12]  B. Descamps-Latscha,et al.  Elevated circulating levels of interleukin-6 in patients with chronic renal failure. , 1991, Kidney international.

[13]  H. Malluche,et al.  Effects of 1,25(OH)2D3 administration on bone in patients with renal failure. , 1990, Kidney international. Supplement.

[14]  H. Malluche,et al.  Renal bone disease 1990: an unmet challenge for the nephrologist. , 1990, Kidney international.

[15]  M. Haubitz,et al.  Hemodialysis-associated induction of cytokines. , 1990, Blood purification.

[16]  B. Descamps-Latscha,et al.  Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. , 1990, Kidney international.

[17]  C. Kauffman,et al.  Mucormycosis: association with deferoxamine therapy. , 1989, The American journal of medicine.

[18]  J. Cavaillon,et al.  In vivo induction of interleukin-1 during hemodialysis. , 1989, Kidney international.

[19]  H. Malluche,et al.  1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. , 1989, Kidney international.

[20]  H. Malluche,et al.  1,25(OH) 2 D 3 administration in moderate renal failure , 1989 .

[21]  O. Niimi,et al.  Effect of deferoxamine mesylate on the growth of mucorales. , 1989, Nephron.

[22]  P. Vergauwe,et al.  Deferoxamine does not increase the risk for bacteremia in hemodialysis patients. , 1989, Nephron.

[23]  B. Boudailliez,et al.  Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. , 1989, Nephron.

[24]  L. Schiller,et al.  Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. , 1989, The Journal of clinical investigation.

[25]  C. de Vroey,et al.  The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. , 1988, Clinical nephrology.

[26]  J. Cavaillon,et al.  Complement activation and induction of interleukin-1 production during hemodialysis. , 1988, Contributions to nephrology.

[27]  M. Blumenstein,et al.  Altered interleukin-1 production in patients undergoing hemodialysis. , 1988, Nephron.

[28]  C. Dinarello,et al.  Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. , 1988, Nephron.

[29]  C. Dinarello,et al.  Induction of tumor necrosis factor during extracorporeal blood purification. , 1987, The New England journal of medicine.

[30]  T. Luger,et al.  Blood-membrane interaction in hemodialysis leads to increased cytokine production. , 1987, Kidney international.

[31]  C. Dinarello,et al.  Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. , 1987, Lymphokine research.

[32]  H. Malluche,et al.  Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients. , 1986, Kidney international.

[33]  H. Malluche,et al.  14 Renal Bone Disease , 1986 .

[34]  H. Malluche,et al.  Atlas of Mineralized Bone Histology , 1986 .

[35]  E. Ritz,et al.  Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. , 1986, The Journal of laboratory and clinical medicine.

[36]  A. Fournier,et al.  Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. , 1986, Kidney international. Supplement.

[37]  H. Malluche,et al.  The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. , 1984, The New England journal of medicine.

[38]  A. Freemont,et al.  Detection and distribution of aluminium in bone. , 1984, Journal of clinical pathology.

[39]  F. Llach,et al.  Prevalence of Various Types of Bone Disease in Dialysis Patients , 1984 .

[40]  S. Teitelbaum.  Renal osteodystrophy. , 1984, Human Pathology.

[41]  F. Llach,et al.  The Effects of Calciferol and its Metabolites on Patients With Chronic Renal Failure , 1983 .

[42]  S. Ott,et al.  Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. , 1983, Annals of internal medicine.

[43]  E. Slatopolsky,et al.  Suppression of parathyroid hormone secretion by aluminum. , 1983, Kidney international.

[44]  V. Jorgetti,et al.  Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathological study. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[45]  S. Ott,et al.  Bone aluminum and histomorphometric features of renal osteodystrophy. , 1982, The Journal of clinical endocrinology and metabolism.

[46]  J. Zingraff,et al.  Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. , 1981, Kidney international.

[47]  S. Massry,et al.  Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. , 1980, Kidney international.

[48]  J. H. Kaye,et al.  Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. , 1975, The Journal of clinical endocrinology and metabolism.

[49]  J. Wergedal,et al.  Quantitative histological studies on the pathogenesis of uremic bone disease. , 1974, The Journal of clinical endocrinology and metabolism.

[50]  S. Massry,et al.  Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. , 1973, Annals of internal medicine.

[51]  R. Lillie,et al.  Histopathologic Technic and Practical Histochemistry , 1954 .

[52]  J. Goldner.  A modification of the masson trichrome technique for routine laboratory purposes. , 1938, The American journal of pathology.